Editorial: Treating children with chronic myeloid leukemia in the imatinib era: A therapeutic dilemma?

Medical and Pediatric Oncology

Volumn 41, Issue 2, 2003, Pages 115-117

  Thornley, Ian ^b   Perentesis, John P ^b   Davies, Stella M ^a,b   Smith, Franklin O ^c   Champagne, Martin ^d   Lipton, Jeffrey M ^e  

^a CHILDREN S ONCOLOGY GROUP   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF MONTREAL   (Canada)

^e SCHNEIDER CHILDREN'S HOSPITAL   (United States)

Author keywords

Bone marrow transplant; CML; Imatinib

Indexed keywords

CYTARABINE; IMATINIB; INTERFERON; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DRUG ACTIVITY; DRUG EFFECT; DRUG RESPONSE; DRUG SCREENING; EDITORIAL; FOLLOW UP; HEALTH SURVEY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MEDICAL SPECIALIST; OUTCOMES RESEARCH; PARENT; PHYSICIAN; PRIORITY JOURNAL; SALVAGE THERAPY;

ANTINEOPLASTIC AGENTS; CHILD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PYRIMIDINES;

EID: 0038714747     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/mpo.10306     Document Type: Editorial

References (10)

1. Castro-Malaspina H, Schaison G, Briere J, et al. Philadelphia chromosome-positive chronic myelocytic leukemia in children: Survival and prognostic factors. Cancer 1983;52:721-727.
2. Clift RA, Appelbaum FR, Thomas ED. Treatment of chronic myeloid leukemia by marrow transplantation. Blood 1993;82:1954-1956.
3. Cwynarski K, Roberts IAG, Brand R, et al. Stem cell transplantation for chronic myeloid leukemia in children [abstract]. Blood 2001;98:814a.
4. Dini G, Rondelli R, Miano M, et al. Unrelated-donor bone marrow transplantation for Philadelphia chromosome-positive chronic myelogenous leukemia in children: Experience of eight European countries. The EBMT Paediatric Diseases Working Party. Bone Marrow Transplant 1996;18:80-85.
5. Gamis AS, Haake R, McGlave P, et al. Unrelated-donor bone marrow transplantation for Philadelphia chromosome-positive chronic myelogenous leukemia in children. J Clin Oncol 1993;11:834-838.
6. Davies SM, DeFor TE, McGlave PB, et al. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med 2001;110:339-346.
7. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
8. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-652.
9. Druker BJ, for the International Randomized IFN vs. STI571 Study Group. STI571 versus interferon+cytarabine as initial therapy for patients with CML: Results of a randomized study [abstract]. J Clin Oncol 2002;21:1a.
10. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998;352:1087-1092.